20:30 , Aug 17, 2018 |  BioCentury  |  Finance

Location, location, biotech

Chinese real estate investor Xuechao Wang placed a bet on a domestic cancer start up 16 years ago, which helped pave the way for the country’s first homegrown targeted cancer therapy. Now, market growth in...
22:10 , Aug 7, 2018 |  BC Extra  |  Preclinical News

Blood-based assay could predict Tecentriq's benefit in NSCLC

A blood-based tumor mutation burden (bTMB) assay could predict anti-PD-L1 mAb Tecentriq atezolizumab's clinical benefit in non-small cell lung cancer patients. The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), Foundation Medicine Inc. (NASDAQ:FMI) and academic...
21:48 , Aug 6, 2018 |  BC Extra  |  Company News

India's Glenmark grants China's Harbour rights to bispecific mAb for cancer

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize GBR 1302 in Greater China. According to BioCentury’s BCIQ database, the deal is Glenmark’s first with a Chinese...
16:38 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said Tradjenta linagliptin met the primary endpoint of improving time to first occurrence of a major cardiovascular event (MACE), including CV death, non-fatal...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other molecule...
20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer (NSCLC)...
17:21 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Takeda's Alunbrig meets in Phase III for first-line NSCLC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said first-line treatment with Alunbrig brigatinib met the primary endpoint of improving independent review committee (IRC)-assessed progression-free survival (PFS) vs. Xalkori crizotinib in the Phase III ALTA-1L trial to treat...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25 patients...
00:04 , Jul 27, 2018 |  BC Extra  |  Clinical News

AZ reveals another Phase III selumetinib miss

AstraZeneca plc (LSE:AZN; NYSE:AZN) disclosed in its 2Q18 earnings that it discontinued development of selumetinib to treat differentiated thyroid cancer after the candidate missed the primary endpoint in the Phase III ASTRA trial in the...
22:30 , Jul 23, 2018 |  BC Extra  |  Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...